Literature DB >> 2557432

Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm.

N Benjamin1, J R Cockcroft, J G Collier, C T Dollery, J M Ritter, D J Webb.   

Abstract

1. The function of angiotensin converting enzyme was investigated in twenty-four healthy men. Forearm blood flow was measured under basal conditions and during administration of enalaprilat (a converting enzyme inhibitor) and/or peptide substrates of converting enzyme into the left brachial artery. Blood flow was compared in the two arms. 2. Enalaprilat had no effect on basal blood flow. The concentration of enalaprilat in venous blood from the control arm was low, and plasma renin activity was not increased, indicating that systemic inhibition of converting enzyme did not occur. 3. Effects of angiotensin and of bradykinin, administered intra-arterially, were limited to the infused arm. Enalaprilat (13 nmol min-1) inhibited converting enzyme in the infused arm, in which it caused approximately a 100-fold reduction in sensitivity to angiotensin I, while having no effect on the vasoconstriction caused by angiotensin II. Enalaprilat increased vasodilatation caused by bradykinin. 4. Aspirin, an inhibitor of cyclo-oxygenase, did not inhibit vasodilatation caused by bradykinin whether infused alone or with enalaprilat, indicating that these responses are not mediated by prostaglandins. 5. We conclude that under basal conditions neither conversion of angiotensin I to angiotensin II nor degradation of bradykinin determines resistance vessel tone in the human forearm. Converting enzyme may affect vascular tone in situations in which intravascular concentrations of peptides are increased over those present under basal conditions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2557432      PMCID: PMC1190590          DOI: 10.1113/jphysiol.1989.sp017630

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  35 in total

1.  Vasopressin stimulates thromboxane synthesis in the toad urinary bladder: effects of imidazole.

Authors:  R M Burch; D R Knapp; P V Halushka
Journal:  J Pharmacol Exp Ther       Date:  1979-09       Impact factor: 4.030

Review 2.  Localization and properties of angiotensin receptors.

Authors:  F A Mendelsohn
Journal:  J Hypertens       Date:  1985-08       Impact factor: 4.844

3.  Effect of bradykinin and thrombin on prostacyclin synthesis in endothelial cells from calf and pig aorta and human umbilical cord vein.

Authors:  S L Hong
Journal:  Thromb Res       Date:  1980-06-15       Impact factor: 3.944

4.  Glucocorticoids, lungs and prostaglandins.

Authors:  G J Blackwell; R J Flower
Journal:  Bull Eur Physiopathol Respir       Date:  1981

Review 5.  Pharmacology of bradykinin and related kinins.

Authors:  D Regoli; J Barabé
Journal:  Pharmacol Rev       Date:  1980-03       Impact factor: 25.468

6.  Role of endothelial cells in relaxation of isolated arteries by bradykinin.

Authors:  P D Cherry; R F Furchgott; J V Zawadzki; D Jothianandan
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

7.  A microassay for active and total renin concentration in human plasma based on antibody trapping.

Authors:  J A Millar; B J Leckie; J J Morton; J Jordan; M Tree
Journal:  Clin Chim Acta       Date:  1980-02-14       Impact factor: 3.786

8.  Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system.

Authors:  J Biollaz; J L Schelling; B Jacot Des Combes; D B Brunner; G Desponds; H R Brunner; E H Ulm; M Hichens; H J Gomez
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

9.  Phorbol ester and 1-oleoyl-2-acetylglycerol inhibit angiotensin activation of phospholipase C in cultured vascular smooth muscle cells.

Authors:  T A Brock; S E Rittenhouse; C W Powers; L S Ekstein; M A Gimbrone; R W Alexander
Journal:  J Biol Chem       Date:  1985-11-15       Impact factor: 5.157

10.  Enalapril maleate (MK-421), a potent, nonsulfhydryl angiotensin-converting enzyme inhibitor: absorption, disposition, and metabolism in man.

Authors:  E H Ulm
Journal:  Drug Metab Rev       Date:  1983       Impact factor: 4.518

View more
  32 in total

1.  Assessment of forearm vasodilator responses to acetylcholine and albuterol by strain gauge plethysmography: reproducibility and influence of strain gauge placement.

Authors:  H A Walker; G Jackson; J M Ritter; P J Chowienczyk
Journal:  Br J Clin Pharmacol       Date:  2001-03       Impact factor: 4.335

Review 2.  Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications.

Authors:  I B Wilkinson; D J Webb
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

3.  Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure.

Authors:  N C Davidson; W J Coutie; D J Webb; A D Struthers
Journal:  Heart       Date:  1996-06       Impact factor: 5.994

4.  Gradual reactivation of vascular angiotensin I to angiotensin II conversion during chronic ACE inhibitor therapy in patients with diabetes mellitus.

Authors:  D C Sharman; A D Morris; A D Struthers
Journal:  Diabetologia       Date:  2007-08-04       Impact factor: 10.122

5.  Ouabain and responses to endothelium-dependent vasodilators in the human forearm.

Authors:  R G Woolfson; N Benjamin; S D Todd; L Poston; J M Ritter
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

Review 6.  Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

7.  Effect of enalapril and quinapril on forearm vascular ACE in man.

Authors:  D Lyons; J Webster; N Benjamin
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

Review 8.  Future Treatment of Hypertension: Shifting the Focus from Blood Pressure Lowering to Arterial Stiffness Modulation?

Authors:  Henry Fok; J Kennedy Cruickshank
Journal:  Curr Hypertens Rep       Date:  2015-08       Impact factor: 5.369

9.  Dual blockade of the renin-angiotensin system with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs).

Authors:  J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

10.  Effect of aspirin on vasodilation to bradykinin and substance P in patients with heart failure treated with ACE inhibitor.

Authors:  Andrew P Davie; John J V McMurray
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.